KyungDong Pharm Co., Ltd. will release the combination hypertension treatment drug “Valdipine Tablet” on October 1st. Valdipine tablets are a combination anti-hypertensive drug whose main ingredients are Amlodipine besylate of the CCB class and Valsartan of the ARB class. Valdipine tablets are the first CCB + ARB combination drug and are the same as the well-known Expo drug, forming an annual market worth 80 billion won. In particular, Amlodipine, a component of Valdipine tablets, is the ingredient with the largest market share among CCB-based preparations, and Valsartan is the ingredient with the largest market share among ARB-based preparations. As such, Valdipine tablets, which are released as a combination of ingredients with the highest prescription rate in each class, are expected to serve as a growth engine in the existing hypertension treatment market. In addition, as the recent paradigm of hypertension treatment has changed to the combination or combination administration of CCB and ARB, the potential growth potential is expected to be very large. Valdipine tablets are released in three strength combinations of Amlodipine and Valsartan, 5/80, 5/160, and 10/160mg, respectively, providing a wide range of choices for combination administration. KyungDong Pharm Co., Ltd., which has been a strong player in the circulatory system market, especially in the hypertension treatment market, is expected to launch Valdipine Tablet as a leader in the company's future growth.

 

☆ Product Information ☆

 

Valdipine tablets 5/80mg

Valdipine tablets 5/160mg

Valdipine Tablet 10/160mg

Ingredient content

Amlodipine besylate 5mg

Valsartan 80mg

Amlodipine besylate 5mg

Valsartan 160mg

Amlodipine besylate 10mg

Valsartan 160mg

Indications

Essential hypertension whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy

Dosage and usage

The recommended dosage is 1 tablet once a day, taken with water regardless of meals.

If possible, it is recommended to take it at the same time every day.

It is recommended to adjust the dosage of each ingredient before administering this medicine, but if blood pressure is not controlled with monotherapy with each ingredient, you can consider switching to this medicine right away.

Reimbursement Code

648103300

648103280

648103290

 

※ For other details, please refer to the product manual.